BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Greco R, De Icco R, Demartini C, Zanaboni AM, Tumelero E, Sances G, Allena M, Tassorelli C. Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine? J Headache Pain 2020;21:122. [PMID: 33066724 DOI: 10.1186/s10194-020-01189-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Fila M, Sobczuk A, Pawlowska E, Blasiak J. Epigenetic Connection of the Calcitonin Gene-Related Peptide and Its Potential in Migraine. Int J Mol Sci 2022;23:6151. [PMID: 35682830 DOI: 10.3390/ijms23116151] [Reference Citation Analysis]
2 Sabina S, Panico A, Mincarone P, Leo CG, Garbarino S, Grassi T, Bagordo F, De Donno A, Scoditti E, Tumolo MR. Expression and Biological Functions of miRNAs in Chronic Pain: A Review on Human Studies. Int J Mol Sci 2022;23:6016. [PMID: 35682695 DOI: 10.3390/ijms23116016] [Reference Citation Analysis]
3 Basedau H, Sturm LM, Mehnert J, Peng KP, Schellong M, May A. Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target - an fMRI study. Elife 2022;11:e77146. [PMID: 35604755 DOI: 10.7554/eLife.77146] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tesfay B, Karlsson WK, Moreno RD, Hay DL, Hougaard A. Is calcitonin gene-related peptide a reliable biochemical marker of migraine? Curr Opin Neurol 2022;35:343-52. [PMID: 35674078 DOI: 10.1097/WCO.0000000000001053] [Reference Citation Analysis]
5 Ferreira KS, Dhillon H, Velly AM. The role of a potential biomarker in patients with migraine: review and new insights. Expert Rev Neurother 2021;21:817-31. [PMID: 34210227 DOI: 10.1080/14737175.2021.1951236] [Reference Citation Analysis]
6 Nowaczewska M, Straburzyński M, Waliszewska-Prosół M, Meder G, Janiak-Kiszka J, Kaźmierczak W. Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine-A Real-Life Study. Front Neurol 2022;13:895476. [PMID: 35655615 DOI: 10.3389/fneur.2022.895476] [Reference Citation Analysis]
7 Harder AVE, Vijfhuizen LS, Henneman P, Willems van Dijk K, van Duijn CM, Terwindt GM, van den Maagdenberg AMJM. Metabolic profile changes in serum of migraine patients detected using 1H-NMR spectroscopy. J Headache Pain 2021;22:142. [PMID: 34819016 DOI: 10.1186/s10194-021-01357-w] [Reference Citation Analysis]
8 Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S. Predictors of response to erenumab after 12 months of treatment. Brain Behav 2021;11:e2260. [PMID: 34268907 DOI: 10.1002/brb3.2260] [Cited by in F6Publishing: 1] [Reference Citation Analysis]